Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2022—Organic macromolecular compounds
  • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
  • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/16—Amides, e.g. hydroxamic acids
  • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2009—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2004—Excipients; Inactive ingredients
  • A61K9/2013—Organic compounds, e.g. phospholipids, fats
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/2095—Tabletting processes
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/20—Pills, tablets, discs, rods
  • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
  • A61K9/2806—Coating materials
  • A61K9/2833—Organic macromolecular compounds
  • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
  • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
  • C07D487/04—Ortho-condensed systems
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Definitions

• the present disclosure relates to methods of making and using pharmaceutical compositions comprising cyclic guanylate monophosphate (cGMP)-specific phosphodiesterase type 9 inhibitors (hereinafter referred to as PDE9 inhibitors).
• cGMP cyclic guanylate monophosphate
• PDE9 inhibitors cyclic guanylate monophosphate-specific phosphodiesterase type 9 inhibitors
• Sickle Cell Disease also called sickle cell anemia (SCA)
• SCD sickle cell anemia
• HBB hemoglobin
• HbS abnormal sickle hemoglobin
• Sickled red blood cells result in chronic inflammation, elevated cell adhesion, oxidative stress, and endothelial dysfunction culminating in vaso-occlusive processes.
• the present disclosure provides methods of making and using Compound 1 and/or pharmaceutical compositions comprising Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, to treat sickle cell disease.
• an oral pharmaceutical composition comprises: about 100 mg to about 300 mg of 6-[(3S,4S)-4-methyl-l-(pyrimidin-2-ylmethyl)pyrrolidin-3- yl]-3-tetrahydropyran-4-yl-7H-imidazo[l,5-a]pyrazin-8-one (Compound 1), or a
• the pharmaceutical composition is in the form of a solid tablet suitable for administration to a patient.
• the composition has a friability of no more than about 0.3% weight loss and a has a disintegration time of less than about 15 minutes, as determined by USP friability and USP disintegration tests.
• the composition has at least one of a friability of no more than about 0.3% weight loss or a disintegration time of less than about 15 minutes, as determined by USP friability and USP disintegration tests.
• the pharmaceutical composition above further comprises hydroxypropyl cellulose (HPC).
• the hydroxypropyl cellulose (HPC) is present in an amount from about 0.4% to about 0.5% by weight.
• the hydroxypropyl cellulose (HPC) is present in an amount of about 0.5% by weight.
• the composition has a hardness of about 10 kPa and/or a thickness of about 4.50 to about 4.80 mm.
• the composition comprises pre- gelatinized starch, colloidal silicon dioxide, and magnesium stearate at a weight ratio of 5:2: 1.
• the coating is about 2.5% by weight of the total tablet.
• an oral pharmaceutical composition comprises: from about 100 mg to about 300 mg of 6-[(3S,4S)-4-methyl-l-(pyrimidin-2- ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[l,5-a]pyrazin-8-one (Compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof; about 5% by weight of pre-gel atinized starch; about 20% by weight of microcrystalline cellulose; about 2% by weight of colloidal silicon dioxide; and about 1% by weight of magnesium stearate, the
• composition is in the form of a solid tablet.
• the composition has a friability of no more than about 0.3% weight loss and/or a disintegration time of less than about 15 minutes, as determined by USP friability and USP disintegration tests.
• HPC hydroxypropyl cellulose
• An oral pharmaceutical composition comprises 6-[(3S,4S)-4-methyl-l-(pyrimidin-2- ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[l,5-a]pyrazin-8-one (Compound 1), or a pharmaceutically acceptable salt, solvate, or polymorph thereof; the pharmaceutical composition is in the form of a solid tablet.
• the filler is microcrystalline cellulose or pre-gelatinized starch.
• the composition comprises about 4% to about 6% by weight of pre- gelatinized starch.
• the composition comprises about 15 mg to about 25 mg of pre-gelatinized starch per tablet.
• the composition further comprises at least a processing aid.
• the processing aid is colloidal silicon dioxide and/or magnesium stearate.
• the composition comprises about 1% to about 2.5% by weight of colloidal silicon dioxide and/or about 0.5% to about 1.5% by weight of magnesium stearate.
• the composition comprises about 6mg to about 8 mg colloidal silicon dioxide and/or about 2 mg to about 4 mg of magnesium stearate per tablet.
• the coating is about 2.5% by weight of the tablet. In some embodiments, the composition comprises about 20 mg to about 40 mg of the coating per tablet. In some embodiments, the composition comprises pre-gelatinized starch, colloidal silicon dioxide, and magnesium stearate at a weight ratio of 5:2: 1. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or polymorph thereof, is present in an amount of about 30mg, 50mg, lOOmg, 150 mg, 200mg, 250 mg, 300 mg, or 350 mg. In some embodiments,
• Compound 1, or a pharmaceutically acceptable salt or polymorph thereof is present in the composition in an amount from about 50% to about 80% or from about 60% to about 75% by weight of the solid tablet. In some embodiments, Compound 1, or a pharmaceutically acceptable salt or polymorph thereof, is present in the composition in an amount 65%, about 68%, about 70%, about 72%, or about 75% by weight of the solid tablet. In some embodiments, the composition has a friability and/or a disintegration time. In some
• the composition has a friability of no more than 0.3% weight loss and/or a disintegration time of less than about 15 minutes, friability and disintegration time are determined by USP testing.
• the composing further comprises 0.4% to about 0.5% by weight of hydroxypropyl cellulose.
• a method for treating sickle cell disease in a subject in need comprises administering any of the pharmaceutical compositions above.
• the pharmaceutical composition is taken with food.
• the pharmaceutical composition is administered once per day, twice per day, or three times per day.
• the pharmaceutical composition is administered once per day.
• the pharmaceutical composition is administered for at least 4 weeks, 12 weeks, 16 weeks, or 24 weeks.
• the method further comprises administering hydroxyurea (HU).
• the method comprises administering to the subject about 0.3 mg/kg to about 6.0 mg/kg or from about 0.3 mg/kg to about 1.0 mg/kg of subjects body mass per day or per dose of Compound 1, or a pharmaceutically acceptable salt or polymorph thereof.
• Fig. 1 shows Compound 1 reduces myeloid and neutrophil inflammatory markers in the lungs of Townes mice.
• Fig. 2 shows Compound 1 reduces adhesion of SCD patient neutrophils to endothelial cell lined microfluidic chamber in vitro.
• Fig. 3 shows Compound 1 reduces expression of CD1 la, CD1 lb and CD 18 integrins on SCD patient neutrophils.
• Fig. 4 shows a chart of comparison between Compound 1 and hydroxyurea showing the superior efficacy of Compound 1.
• Fig. 5 shows the outcome of studies in the Townes SCD Model comparing Compound 1 (30 mg/kg).
• Fig. 6 shows the outcome of studies in the Townes SCD Model comparing Compound 1 (30 mg/kg).
• Fig. 7 illustrates a clinical study design for Compound 1.
• FIG. 8 depicts, without limitation, a representative sampling of screenshots for use in a mobile device running software designed to track human impact of a pharmaceutical.
• Phosphodiesterases are a family of enzymes degrading cyclic nucleotides and thereby regulating the cellular levels of second messengers throughout the entire body. PDEs represent attractive drug targets, as proven by a number of compounds that have been introduced to clinical testing and the market, respectively. PDEs are encoded by 21 genes that are functionally separated into 11 families differing with respect to kinetic properties, substrate selectivity, expression, localization pattern, activation, regulation factors and inhibitor sensitivity.
• PDEs The function of PDEs is the degradation of the cyclic nucleotide monophosphates cyclic Adenosine Monophosphate (cAMP) and/or Guanosine Monophosphate (cGMP), which are important intracellular mediators involved in numerous vital processes including the control of neurotransmission and smooth muscle contraction and relaxation.
• cAMP cyclic Adenosine Monophosphate
• cGMP Guanosine Monophosphate
• PDE9 is cGMP specific (K m cAMP is >1000c for cGMP) and is hypothesized to be a key player in regulating cGMP levels as it has the lowest K m among the PDEs for this nucleotide. PDE9 is expressed throughout the brain at low levels with the potential for regulating basal cGMP.
• PDE9 expression is highest in prostate, intestine, kidney and haematopoietic cells, enabling therapeutic potential in various non-CNS indications.
• compositions comprising PDE9 inhibitors are designed for treatment for Sickle Cell Disease (SCD).
• a compound is considered to be a PDE9 inhibitor if the amount required to reach the 50% inhibition level PDE9 is 10 micromolar or less, preferably less than 9 micromolar, such as 8 micromolar or less, such as 7 micromolar or less, such as 6 micromolar or less, such as 5 micromolar or less, such as 4 micromolar or less, such as 3 micromolar or less, more preferably 2 micromolar or less, such as 1 micromolar or less, in particular 500 nM or less.
• the required amount of PDE9 inhibitor required to reach the IC 50 level of PDE9 is 400nM or less, such as 300 nM or less, 200nM or less, 100 nM or less, or even 80 nM or less, such as 50 nM or less, for example 25 nM or less.
• the PDE9 inhibitor of the present disclosure has low or no blood brain barrier penetration.
• the ratio of the concentration of a PDE9 inhibitor of the present disclosure in the brain to the concentration of it in the plasma may be less than about 0.50, about 0.40, about 0.30, about 0.20, about 0.10, about 0.05, about 0.04, about 0.03, about 0.02, or about 0.01.
• the brain/plasma ration is measured 30 min or 120 min after administration of the PDE9 inhibitor.
• the PDE9 inhibitor may be any imidazo pyrazinone PDE9 inhibitor disclosed in WO 2013/053690 and/or any imidazo triazinone PDE9 inhibitor disclosed in WO 2013/110768, the contents of each of which are incorporated herein by reference in their entirety.
• the PDE9 inhibitor is Compound 1 or a pharmaceutically acceptable salt, cocrystal, solvate, or polymorph thereof.
• a racemate form of Compound 1 and an anhydrous form of Compound 1 have been described in WO 2013/053690 and WO
• the PDE9 inhibitor is 6-[(3S,4S)-4-methyl-l-(pyrimidin- 2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[l,5-a]pyrazin-8-one
• Compound 1 has the following structure:
• Compound 1 is enantiopure or substantially enantiopure.
• the present disclosure further provides a pharmaceutical composition comprising a therapeutically effective amount of any of the PDE9 inhibitors and a pharmaceutically acceptable carrier or diluent.
• the present disclosure provides a pharmaceutical composition comprising a therapeutically effective amount of Compound 1, or a pharmaceutically acceptable salt or polymorph thereof, and a pharmaceutically acceptable carrier or diluent or excipient.
• the present disclosure also comprises salts of the PDE9 inhibitors, typically, pharmaceutically acceptable salts.
• Such salts include pharmaceutically acceptable acid addition salts.
• Acid addition salts include salts of inorganic acids as well as organic acids.
• suitable inorganic acids include hydrochloric, hydrobromic, hydroiodic, phosphoric, sulfuric, sulfamic, nitric acids and the like.
• suitable organic acids include formic, acetic, trichloroacetic, propionic, benzoic, cinnamic, citric, fumaric, glycolic, itaconic, lactic, methanesulfonic, maleic, malic, malonic, mandelic, oxalic, picric, pyruvic, salicylic, succinic, methane sulfonic, ethanesulfonic, tartaric, ascorbic, pamoic, bismethylene salicylic, ethanedi sulfonic, gluconic, citraconic, aspartic, stearic, palmitic, EDTA, glycolic, p-aminobenzoic, glutamic,
• the compounds of this disclosure may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
• pharmaceutically acceptable solvents such as water, ethanol, and the like.
• the solvated forms are considered equivalent to the unsolvated forms for the purposes of this disclosure.
• the pharmaceutical composition comprises Compound 1 as the solvated, unsolvated, or crystalline form. In some embodiments, Compound 1 is present as the unsolvated form. In some embodiments, Compound 1 is present as the present as the crystalline form. In some embodiments, Compound 1 is present as a monohydrate crystalline form.
• the compounds of the disclosure may be administered alone or in combination with pharmaceutically acceptable carriers, diluents or excipients, in either single or multiple doses.
• pharmaceutical compositions according to the disclosure may be formulated with pharmaceutically acceptable carriers or diluents as well as any other known adjuvants and excipients in accordance with conventional techniques such as those disclosed in Remington: The Science and Practice of Pharmacy, 22nd Edition, Gennaro, Ed., Mack Publishing Co., Easton, PA, 2013.
• compositions may be specifically formulated for
• the pharmaceutical composition is formulated for oral administration to a subject.
• the pharmaceutical composition is formulated as a tablet or pill.
• the pharmaceutical composition is formulated as a solid tablet suitable for oral administration to a subject.
• compositions for oral administration include solid dosage forms such as capsules, tablets, dragees, pills, lozenges, powders, and granules. Where appropriate, the compositions may be prepared with coatings, such as enteric coatings or they may be formulated so as to provide controlled release of the active ingredient such as sustained or prolonged release according to methods well known in the art.
• Liquid dosage forms for oral administration include solutions, emulsions, suspensions, syrups, and elixirs, either
• compositions for parenteral administration include sterile aqueous and non-aqueous injectable solutions, dispersions, suspensions, or emulsions as well as sterile powders to be reconstituted in sterile injectable solutions or dispersions prior to use.
• Other suitable administration forms include, but are not limited to, suppositories, sprays, ointments, creams, gels, inhalants, dermal patches, and implants.
• the present disclosure also provides a process for making a pharmaceutical composition comprising admixing a therapeutically effective amount of a compound of the present disclosure and at least one pharmaceutically acceptable carrier or diluent.
• the compounds of this disclosure are generally utilized as the free substance or as a pharmaceutically acceptable salt thereof.
• Such salts are prepared in a conventional manner by treating a solution or suspension of a compound of the present disclosure with a
• solutions of the compounds of the present disclosure in sterile aqueous solution aqueous propylene glycol, aqueous vitamin E or sesame or peanut oil may be employed.
• aqueous solutions should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose.
• the aqueous solutions are particularly suitable for intravenous, intramuscular, subcutaneous and intraperitoneal administration.
• the compounds of the present disclosure may be readily incorporated into known sterile aqueous media using standard techniques known to those skilled in the art.
• Suitable pharmaceutical carriers include inert solid diluents or fillers, sterile aqueous solutions and various organic solvents.
• solid carriers include lactose, terra alba, sucrose, cyclodextrin, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and lower alkyl ethers of cellulose.
• liquid carriers include, but are not limited to, syrup, peanut oil, olive oil, phospholipids, fatty acids, fatty acid amines, polyoxyethylene and water.
• the carrier or diluent may include any sustained release material known in the art, such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
• sustained release material such as glyceryl monostearate or glyceryl distearate, alone or mixed with a wax.
• compositions of the present disclosure suitable for oral administration may be presented as discrete units such as capsules or tablets, each containing a predetermined amount of the active ingredient, and optionally a suitable excipient.
• the orally available formulations may be in the form of a powder or granules, a solution or suspension in an aqueous or non-aqueous liquid, or an oil-in-water or water-in-oil liquid emulsion.
• the preparation may be tabletted, placed in a hard gelatine capsule in powder or pellet form or it may be in the form of a troche or lozenge.
• the amount of solid carrier will vary widely but will range from about 25 mg to about 1 g per dosage unit. In some embodiments, the solid carrier will be about 10 mg to about 150 mg per dosage unit.
• the solid carrier will be about 10 mg to about 20 mg, about 10 mg to about 30 mg, about 10 mg to about 40 mg, about 10 mg to about 50 mg, about 10 mg to about 60 mg, about 10 mg to about 70 mg, about 10 mg to about 80 mg, about 10 mg to about 90 mg, about 10 mg to about 100 mg, about 10 mg to about 125 mg, about 10 mg to about 150 mg, about 20 mg to about 30 mg, about 20 mg to about 40 mg, about 20 mg to about 50 mg, about 20 mg to about 60 mg, about 20 mg to about 70 mg, about 20 mg to about 80 mg, about 20 mg to about 90 mg, about 20 mg to about 100 mg, about 20 mg to about 125 mg, about 20 mg to about 150 mg, about 30 mg to about 40 mg, about 30 mg to about 50 mg, about 30 mg to about 60 mg, about 30 mg to about 70 mg, about 30 mg to about 80 mg, about 30 mg to about 90 mg, about 30 mg to about 100 mg, about 30 mg to about 125 mg, about 30 mg to about 150 mg, about 40 mg, about 30
• the solid carrier will be about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, or about 150 mg. In some embodiments, the solid carrier will be at least about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, or about 125 mg. In some embodiments, the solid carrier will be at most about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 125 mg, or about 150 mg per dosage unit.
• the solid carrier will be about 150 mg to about 1,000 mg per dosage unit. In some embodiments, the solid carrier will be about 150 mg to about 175 mg, about 150 mg to about 200 mg, about 150 mg to about 300 mg, about 150 mg to about 400 mg, about 150 mg to about 500 mg, about 150 mg to about 600 mg, about 150 mg to about 700 mg, about 150 mg to about 800 mg, about 150 mg to about 900 mg, about 150 mg to about 1,000 mg, about 175 mg to about 200 mg, about 175 mg to about 300 mg, about 175 mg to about 400 mg, about 175 mg to about 500 mg, about 175 mg to about 600 mg, about 175 mg to about 700 mg, about 175 mg to about 800 mg, about 175 mg to about 900 mg, about 175 mg to about 1,000 mg, about 200 mg to about 300 mg, about 200 mg to about 400 mg, about 200 mg to about 500 mg, about 200 mg to about 600 mg, about 200 mg to about 700 mg, about 200 mg to about 800 mg, about 200 mg to about 900 mg, about 200 mg to about 1,000 mg
• the solid carrier will be about 150 mg, about 175 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, or about 1,000 mg. In some embodiments, the solid carrier will be at least about 150 mg, about 175 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, or about 900 mg. In some embodiments, the solid carrier will be at most about 175 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 700 mg, about 800 mg, about 900 mg, or about 1,000 mg per dosage unit.
• the solid carrier will be about 10 mg, l5mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, or about 1 g per dosage unit.
• the preparation may be in the form of a syrup, emulsion, soft gelatine capsule or sterile injectable liquid such as an aqueous or non-aqueous liquid suspension or solution
• the solid carrier will be about 1 g to about 2 g per dosage unit. In some embodiments, the solid carrier will be about 1 g to about 1.1 g, about 1 g to about 1.2 g, about 1 g to about 1.3 g, about 1 g to about 1.4 g, about 1 g to about 1.5 g, about 1 g to about 1.6 g, about 1 g to about 1.7 g, about 1 g to about 1.8 g, about 1 g to about 1.9 g, about 1 g to about 2 g, about 1.1 g to about 1.2 g, about 1.1 g to about 1.3 g, about 1.1 g to about 1.4 g, about 1.1 g to about 1.5 g, about 1.1 g to about 1.6 g, about 1.1 g to about 1.7 g, about 1.1 g to about 1.8 g, about 1.1 g to about 1.9 g, about 1.1 g to about 2 g, about 1.2 g, about 1.1 g to
• the solid carrier will be about 1 g, about 1.1 g, about 1.2 g, about 1.3 g, about 1.4 g, about 1.5 g, about 1.6 g, about 1.7 g, about 1.8 g, about 1.9 g, or about 2 g. In some embodiments, the solid carrier will be at least about 1 g, about 1.1 g, about 1.2 g, about 1.3 g, about 1.4 g, about 1.5 g, about 1.6 g, about 1.7 g, about 1.8 g, or about 1.9 g.
• the solid carrier will be at most about 1.1 g, about 1.2 g, about 1.3 g, about 1.4 g, about 1.5 g, about 1.6 g, about 1.7 g, about 1.8 g, about 1.9 g, or about 2 g per dosage unit.
• the pharmaceutical compositions of the disclosure may be prepared by conventional methods in the art.
• tablets may be prepared by mixing the active ingredient with ordinary adjuvants and/or diluents and subsequently compressing the mixture in a conventional tabletting machine prepare tablets.
• adjuvants or diluents comprise: corn starch, potato starch, talcum, magnesium stearate, gelatin, lactose, gums, and the like. Any other adjuvants or additives usually used for such purposes such as colorings, flavorings, preservatives etc. may be used provided that they are compatible with the active ingredients.
• the pharmaceutical composition comprises PDE9 inhibitor Compound 1.
• the pharmaceutical composition comprises at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% by weight of PDE9 inhibitors of the present disclosure.
• the pharmaceutical composition comprises at least about 1 % to about 90 % by weight of PDE9 inhibitors of the present disclosure.
• the pharmaceutical compositions comprises at least about 1 % to about 10 %, about 1 % to about 20 %, about 1 % to about 30 %, about 1 % to about 40 %, about 1 % to about 50 %, about 1 % to about 60 %, about 1 % to about 70 %, about 1 % to about 80 %, about 1 % to about 90 %, about 10 % to about 20 %, about 10 % to about 30 %, about 10 % to about 40 %, about 10 % to about 50 %, about 10 % to about 60 %, about 10 % to about 70 %, about 10 % to about 80 %, about 10 % to about 90 %, about 20 % to about 30 %, about 20 % to about 40 %, about 20 % to about 50 %, about 20 % to about 60 %, about 20 % to about 70 %, about 20 % to about 80 %, about 20 % to about 90 %, about 30 % to about 40
• the pharmaceutical compositions comprise at least about 1 %, about 10 %, about 20 %, about 30 %, about 40 %, about 50 %, about 60 %, about 70 %, about 80 %, or about 90 %.
• the pharmaceutical compositions comprises at least at least about 1 %, about 10 %, about 20 %, about 30 %, about 40 %, about 50 %, about 60 %, about 70 %, or about 80 %.
• the pharmaceutical compositions comprises at least at most about 10 %, about 20 %, about 30 %, about 40 %, about 50 %, about 60 %, about 70 %, about 80 %, or about 90 % by weight of PDE9 inhibitors of the present disclosure.
• the pharmaceutical composition comprises at least about 90 % to about 99.9 % by weight of PDE9 inhibitors of the present disclosure.
• the pharmaceutical composition comprises at least about 90 % to about 91 %, about 90 % to about 92 %, about 90 % to about 93 %, about 90 % to about 94 %, about 90 % to about 95 %, about 90 % to about 96 %, about 90 % to about 97 %, about 90 % to about 98 %, about 90 % to about 99 %, about 90 % to about 99.9 %, about 91 % to about 92 %, about 91
• the pharmaceutical composition comprises at least about 90 %, about 91 %, about 92 %, about 93 %, about 94 %, about 95 %, about 96 %, about 97 %, about 98 %, about 99 %, or about 99 % to about 99.9 %.
• the pharmaceutical compositions comprises at least at least about 90 %, about 91 %, about 92 %, about 93 %, about 94 %, about 95 %, about 96 %, about 97 %, about 98 %, or about 99 %.
• the pharmaceutical composition comprises at least at most about 91 %, about 92 %, about 93 %, about 94 %, about 95 %, about 96 %, about 97 %, about 98 %, about 99 %, or about 99.9 % by weight of PDE9 inhibitors of the present disclosure.
• the pharmaceutical composition comprise at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% by weight of PDE9 inhibitors of the present disclosure.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is formulated as a pharmaceutical composition for oral administration.
• the composition for oral administration comprises at least a filler and/or a processing aid.
• the processing aid may be a glidant or a lubricant.
• the composition for oral administration may also comprise a coating.
• the composition for oral administration comprises microcrystalline cellulose and/or pre-gelatinized starch as fillers.
• the composition for oral administration comprises colloidal silicon dioxide and/or magnesium stearate as processing aids.
• the composition for oral administration comprises Opadry® II white film coating.
• Opadry® II is a high productivity, water soluble, pH independent complete dry powder film coating system containing polymer, plasticizer and pigment which allows for immediate disintegration for fast, active release.
• the composition for oral administration comprises purified water, which is removed during processing.
• the tablet comprises a coating between about 5% to about 20% by weight of the total weight of the tablet. In some embodiments, the tablet comprises a coating between about 0.5 % to about 10 %. In some embodiments, the tablet comprises a coating between about 0.5 % to about 1 %, about 0.5 % to about 2 %, about 0.5 % to about 3 %, about 0.5 % to about 4 %, about 0.5 % to about 5 %, about 0.5 % to about 6 %, about 0.5 % to about 7 %, about 0.5 % to about 8 %, about 0.5 % to about 9 %, about 0.5 % to about 10 %, about 1 % to about 2 %, about 1 % to about 3 %, about 1 % to about 4 %, about 1 % to about 5 %, about 1 % to about 6 %, about 1 % to about 7 %, about 1 % to about 8 %, about 1 % to about 9 %, about 0.5 % to
• the tablet comprises a coating between about 0.5 %, about 1 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, about 9 %, or about 10 %. In some embodiments, the tablet comprises a coating between at least about 0.5 %, about 1 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, or about 9 %.
• the tablet comprises a coating between at most about 1 %, about 2 %, about 3 %, about 4 %, about 5 %, about 6 %, about 7 %, about 8 %, about 9 %, or about 10 %. In some embodiments, the tablet comprises a coating between about 0.5% about 5%, about 10%, about 15%, or about 20% by weight of the total weight of the tablet.
• the composition further comprises an enteric coating.
• An enteric coating is a polymer barrier applied on oral medication that prevents its dissolution or disintegration in the gastric environment. Tablets, mini-tablets, pellets and granules (usually filled into capsule shells) are the most common enteric-coated dosage forms. Most enteric coatings work by presenting a surface that is stable at the intensely acidic pH found in the stomach, but breaks down rapidly at a higher pH (alkaline pH). For example, they will not dissolve in the gastric acids of the stomach (pH ⁇ 3), but they will in the alkaline (pH 7-9) environment present in the small intestine.
• enteric coating may protect gastric mucosa from the irritating effects of the medication itself.
• enteric coatings include but are not limited to fatty acids, waxes, shellac, plastics, and plant fibers. Conventional materials used are solutions of film resins.
• the pharmaceutical composition comprises a filler.
• the filler is pre-geletinized starch.
• the pharmaceutical composition comprises pre-gel atinized starch between about 4% to about 6% by weight of the total weight of the pharmaceutical composition.
• the pharmaceutical composition comprises pre-gel atinized starch at about 4%, about 5%, or about 6% by weight of the total weight of the pharmaceutical composition.
• the filler is microcrystalline cellulose. In some embodiments, the filler is microcrystalline cellulose.
• the pharmaceutical composition comprises microcrystalline cellulose at between about 15% to about 50% by weight of the total weight of the pharmaceutical composition. In some embodiments, the pharmaceutical composition comprises microcrystalline cellulose at about 50%, about 40%, about 30%, about 20%, or about 15% by weight of the total weight of the pharmaceutical composition. In some embodiments, the pharmaceutical composition comprises about 20% by weight of microcrystalline cellulose.
• the pharmaceutical composition comprises a processing aid.
• the processing aid is colloidal silicon dioxide.
• the pharmaceutical composition comprises colloidal silicon dioxide between about 1% to about 2.5% by weight of the total weight of the pharmaceutical composition.
• the pharmaceutical composition comprises colloidal silicon dioxide at about 1%, about 1.5%, about 2%, or about 2.5% by weight of the total weight of the pharmaceutical composition.
• the processing aid is magnesium stearate.
• the pharmaceutical composition comprises magnesium stearate between about 0.5% to about 1.5% by weight of the total weight of the pharmaceutical composition. In some embodiments, the pharmaceutical composition comprises magnesium stearate at about 0.5%, about 0.8%, about 1.0%, about 1.2%, or about 1.5% by weight of the total weight of the pharmaceutical composition.
• the pharmaceutical composition comprises pre-gelatinized starch, colloidal silicon dioxide, and magnesium stearate at a weight ratio of 5:2: 1.
• the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is stored at controlled room temperature (20-25°C).
• the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is protected from light.
• the pharmaceutical composition has a friability and/or a disintegration time.
• Friability as disclosed herein, is the tendency for a tablet to chip, crumble or break following compression. Friability testing is a laboratory technique to test the durability of tablets. This testing involves repeatedly dropping a sample of tablets over a fixed time, using a rotating wheel with a baffle. Friability is determined by the USP (United States
• the pharmaceutical composition has a friability of no more than about 0.5% weight loss of the tablet. In some embodiments, the pharmaceutical composition has a friability of no more than about 0.4% weight loss of the tablet. In some embodiments, the pharmaceutical composition has a friability of no more than about 0.3% weight loss of the tablet. In some embodiments, the pharmaceutical composition has a friability of no more than about 0.25% weight loss of the tablet.
• Disintegration tests are used to test how a drug in pellet form will disintegrate in solution. These tests can be correlated with the in vitro breakdown of powdered compounds for quality control purposes. Disintegration is defined as that state in which no residue of the unit under test remains on the screen of the apparatus or, if a residue remains, it consists of fragments of disintegrated parts of tablets component parts such as insoluble coating of the tablets or of capsule shells, or of any melted fatty substance. This test is most often performed on products that have known absorption problems or known poor solubility. It is also performed on sustained or delayed release products such as enteric coated products.
• Dissolution testing can be carried out on either capsules or tablets.
• the pharmaceutical composition has a dissolution time of no more than 15 minutes.
• the pharmaceutical composition further comprises hydroxypropyl cellulose.
• Hydroxypropyl cellulose is a derivative of cellulouse with both water and organic solubility. It is often used as a pharmaceutical excipient.
• Hyrdoxypropyl cellulose can be used as a tablet binder, thickening agent, viscosity-increasing agent, a coating agent, and a film forming agent.
• the pharmaceutical composition further comprises from about 1% to about 6% by weight of the table of hydroxypropyl cellulose.
• the pharmaceutical composition further comprises from about 4% to about 5% by weight of the table of hydroxypropyl cellulose.
• hydroxypropyl cellulose is present at about 4% weight of the tablet. In some embodiments, hydroxypropyl cellulose is present at about 5% weight of the tablet. In some embodiments, hydroxypropyl cellulose is present at about 6% weight of the tablet.
• the pharmaceutical composition has a tablet hardness and/or a tablet thickness.
• Tablet hardness testing is a laboratory technique used by the pharmaceutical industry to determine the breaking point and structural integrity of a tablet and find out how it changes under conditions of storage, transportation, packaging and handling before usage.
• the breaking point of a tablet is based on its shape.
• the table has a hardness of about lOkPa.
• the tablet has a thickness of about 4.5 - 5.0 mm.
• the tablet has a thickness of about 4.65 - 4.85mm.
• composition comprising Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is suitable for pediatric uses and can be taken by pediatric sickle cell anemia patients.
• the pharmaceutical composition comprising Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is taken with food. In some embodiments, the pharmaceutical composition, is taken after a meal. In some embodiments, the pharmaceutical composition, is taken without food.
• the oral dosage ranges from about 0.001 to about 100 mg/kg body weight per day. In some embodiments, the oral dosage range is from about 0.01 to about 50 mg/kg body weight per day. In some embodiments, the oral dosage range is from about 0.05 to about 10 mg/kg body weight per day. Oral dosages are usually administered in one or more dosages, typically, one to three dosages per day. In some embodiments, the dose is administered once, twice, or three times a day. The exact dosage will depend upon the frequency and mode of administration, the gender, age, weight, and general health of the subject treated, the nature and severity of the condition treated and any concomitant diseases to be treated and other factors evident to those skilled in the art.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered to a subject in need thereof, at a dose of less than 6.0 mg/kg or less than about 4.0 mg/kg per body weight of the subject. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is administered at a dose of from about 0.1 mg/kg to about 6.0 mg/kg per body weight of the subject. For example, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is administered at a dose of from about 0.3 to about 3.0 mg/kg, or from about 0.3 to about 1.0 mg/kg per body weight of the subject. The patient may have sickle cell disease.
• the patient may be an adult (>18 years old) or a child ( ⁇ 18 years old).
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof at a dose of around 0.3 mg/kg, around 0.2 mg/kg, around 0.1 mg/kg, or around 0.05 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 1 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 3 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 6 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 0.1 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 0.3 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 0.5 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 1 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 5 mg/kg per body weight of the subject.
• the patient receives Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, at about 10 mg/kg per body weight of the subject.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered to a patient in need thereof, at a flat dose of about 20 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400, about 500 mg, or about 600 mg per day.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered to a patient at a dose of about 50 mg, about lOOmg, about 150 mg, about 200 mg, about 250 mg, about 300 mg, or about 350 mg.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 50 mg.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 100 mg. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 150 mg. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 200 mg. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 250 mg. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 300 mg. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 350 mg. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered at a dose of about 400 mg.
• Compound 1 is administered at a maximum dose per day or per dose.
• a total combined dose of lg of Compound 1, or a pharmaceutically acceptable salt, solvate or polymorph thereof is administered per day or per dose.
• a total combined dose of 600 mg Compound 1, or a pharmaceutically acceptable salt, solvate or polymorph thereof is administered per day or per dose.
• a total combined dose of 500 mg Compound 1, or a pharmaceutically acceptable salt, solvate or polymorph thereof is administered per day or per dose.
• a total combined dose of 400 mg Compound 1, or a pharmaceutically acceptable salt, solvate or polymorph thereof is administered per day or per dose.
• a total combined dose of 300 mg Compound 1, or a pharmaceutically acceptable salt, solvate or polymorph thereof is administered per day or per dose. In some embodiments, a total combined dose of 200 mg Compound 1, or a pharmaceutically acceptable salt, solvate or polymorph thereof, is administered per day or per dose. In some embodiments, Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is administered to a patient, wherein Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered once a day. In some embodiments, the pharmaceutical composition is administered twice a day.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered to a patient, wherein Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered once a day with food. It has been found that food can dramatically reduce the adverse event profile. The incidence and severity of the side effects, such as nausea, emesis and headache, can be reduced when Compound 1 or a pharmaceutically acceptable salt or polymorph thereof, is taken with food.
• Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered to a patient, wherein Compound 1 or a pharmaceutically acceptable salt or polymorph thereof is administered once a day for at least 7 days, 10 days, 2 weeks, 3 weeks, 4 weeks, 1 month, 2 months, 3 months, 4 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, a year, 1.5 years, or 2 years.
• the patient is treated for 3 months.
• the patient is treated for 6 months.
• the patient is treated for 1 year.
• the patient is treated for 1.5 years.
• the patient is treated for 2 years, 3 years, 4 years, 5 years, over 5 years, or the duration of life.
• the pharmaceutical compositions are presented in a unit dosage form by methods known to those skilled in the art.
• a typical unit dosage form for oral administration may contain from about 0.01 to about 1000 mg, from about 0.05 to about 500 mg, or from about 0.5 mg to about 200 mg.
• the pharmaceutical composition comprising compounds of the present disclosure is used in combination with an additional active agent, such as
• Hydroxyurea HU
• the compounds of the present disclosure and the additional active agent may be administered simultaneously, sequentially, or at any order.
• the compounds of the present disclosure and the additional active agent may be administered at different dosages, with different dosing frequencies, or via different routes, whichever is suitable.
• administered simultaneously is not specifically restricted and means that the compounds of the present disclosure and the additional active agent are substantially administered at the same time, e.g. as a mixture or in immediate subsequent sequence.
• the term“administered sequentially”, as used herein, is not specifically restricted and means that the compounds of the present disclosure and the additional active agent are not administered at the same time but one after the other, or in groups, with a specific time interval between administrations.
• the time interval may be the same or different between the respective administrations of the compounds of the present disclosure and the additional active agent and may be selected, for example, from the range of 2 minutes to 96 hours, 1 to 7 days or one, two, or three weeks.
• the time interval between the administrations may be in the range of a few minutes to hours, such as in the range of 2 minutes to 72 hours, 30 minutes to 24 hours, or 1 to 12 hours. Further examples include time intervals in the range of 24 to 96 hours, 12 to 36 hours, 8 to 24 hours, and 6 to 12 hours.
• the molar ratio of the compounds of the present disclosure and the additional active agent is not particularly restricted.
• the molar ratio of them may be in the range of 1 :500 to 500: 1, or of 1 : 100 to 100: 1, or of 1 :50 to 50: 1, or of 1 :20 to 20: 1, or of 1 :5 to 5: 1, or 1 :1.
• Similar molar ratios apply when the compounds of the present disclosure and two or more other active agents are combined in a composition.
• the compounds of the present disclosure compounds of the present disclosure may comprise a predetermined molar weight percentage from about 1% to 10%, or about 10% to about 20%, or about 20% to about 30%, or about 30% to 40%, or about 40% to 50%, or about 50% to 60%, or about 60% to 70%, or about 70% to 80%, or about 80% to 90%, or about 90% to 99% of the composition.
• PDE9 is expressed specifically in the human haematopoietic system including neutrophils, reticulocytes erythroid and erythroleukaemic cells. Furthermore, SCD patients exhibit a marked and significant elevation of PDE9 expression in reticulocytes and neutrophils compared to healthy individuals (Almeida et ah, Br J Haematol. 2008 Sep; 142(5), 836).
• PDE9 inhibition ameliorates the increased adhesive properties of SCD neutrophils (Miguel et al., Inflamm Res. 2011 Jul; 60(7), 633).
• the mechanism by which PDE9 inhibition decreases cell adhesion has been shown to be mediated by increased cGMP and decreased endothelial adhesion molecule expression.
• the PDE9 inhibitor-mediated decrease in cell adhesion had the functional effect of increased cell survival.
• HbF fetal non-sickled haemoglobin
• HbS abnormal haemoglobin
• RBCs red blood cells
• PDE9 inhibitors of the present disclosure and hydroxyurea act through different mechanisms.
• HU increases nitric oxide (NO) levels, which activate soluble guanylyl cyclase (sGC) to generate cGMP.
• PDE9 inhibitors of the present disclosure block the degradation of cGMP by inhibiting PDE9 enzymatic activity, thus elevating cGMP levels.
• cGMP binds to protein kinase G (PKG) and signals synthesis of fetal gamma globin and ultimately production of HbF.
• PKG protein kinase G
• HbF protein kinase G
• the direct inhibition of PDE9 activity increases cGMP levels, which promotes decreased leucocyte adhesion.
• One aspect of the present disclosure provides methods of using PDE9 inhibitors of the present disclosure and pharmaceutical compositions comprising PDE9 inhibitors of the present disclosure.
• PDE9 inhibitors of the present disclosure may be used to treat sickle cell disease or any disease and/or symptom related to sickle cell disease, such as anemia, sickle-hemoglobin C disease (SC), vaso-occlusive crisis, attacks of pain (sickle cell crisis), splenic sequestration crisis, acute chest syndrome, aplastic crisis, hemolytic crisis, long-term pain, bacterial infections, and stroke.
• SC sickle-hemoglobin C disease
• PDE9 inhibitors of the present disclosure are used to increase hemoglobin levels in the subject.
• PDE9 inhibitors of the present disclosure are used to increase cGMP levels in a cell or in the plasma of a subject, wherein the subject has sickle cell disease.
• the cell may be, but not limited to, red blood cells and/or white blood cells.
• the cGMP level may be increased by at least 50%, at least 100%, or at least 150%. In some embodiments, the cGMP level may be increased at least 2 times, 3 times, 4 times, 5 times, 10 times, 15 times, 20 times, or 25 times.
• PDE9 inhibitors of the present disclosure are used to increase fetal hemoglobin (HbF) positive red blood cell number in a subject, wherein the subject has sickle cell disease.
• HbF positive red blood cell number is increased by at least 50%, at least 100%, or at least 150%.
• the HbF positive red blood cell number is increased by at least 2 times, 3 times, 4 times, 5 times, 10 times, 15 times, 20 times, or 25 times.
• PDE9 inhibitors of the present disclosure are used to reduce sickle red blood cell percentage (% sickle RBC), stasis percentage (% stasis), total bilirubin, or total leucocyte count in a subject, wherein the subject has sickle cell disease.
• the % sickle RBC, % stasis, total bilirubin, total leucocyte count or spleen weight is decreased by at least 10%, 20%, 30%, 40%, 50%, 60% or 70%.
• cGMP level may be measured with any suitable method in the art, such as enzyme immunoassay.
• HbF positive cells means red blood cells with HbF. HbF positive cells may be measured from a blood sample with any suitable method in the art, such as electrophoresis and/or colorimetric methods.
• Sickle red blood cells, sickled red blood cells, as used herein, means red blood cells with a crescent or sickle shape. % sickle red blood cell may be measured from a blood sample with any suitable method in the art.
• Stasis or microvascular stasis is serious slowing, or complete cessation, of blood or lymph flow through vessels.
• % stasis is the number of static (no flow) venules divided by the number of flowing venules times 100. % stasis may be measured with any suitable method in the art.
• Total bilirubin means both unconjugated and conjugated bilirubin.
• Total bilirubin levels may be measured from a blood sample with any suitable method in the art.
• Total leucocyte count or total white blood cell count is a blood test that measures the number of white blood cells in the body. It may be measured from a blood sample with any suitable method in the art.
• Another aspect of the present disclosure provides methods of using a PDE9 inhibitor of the present disclosure in combination with at least one other active agent. They may be administered simultaneously or sequentially. They may be present as a mixture for simultaneous administration, or may each be present in separate containers for sequential administration.
• the term“simultaneous administration”, as used herein, is not specifically restricted and means that the PDE9 inhibitor of the present disclosure and the at least one other active agent are substantially administered at the same time, e.g. as a mixture or in immediate subsequent sequence.
• the term“sequential administration”, as used herein, is not specifically restricted and means that the PDE9 inhibitor of the present disclosure and the at least one other active agent are not administered at the same time but one after the other, or in groups, with a specific time interval between administrations.
• the time interval may be the same or different between the respective administrations of PDE9 inhibitor of the present disclosure and the at least one other active agent and may be selected, for example, from the range of 2 minutes to 96 hours, 1 to 7 days or one, two or three weeks.
• the time interval between the administrations may be in the range of a few minutes to hours, such as in the range of 2 minutes to 72 hours, 30 minutes to 24 hours, or 1 to 12 hours. Further examples include time intervals in the range of 24 to 96 hours, 12 to 36 hours, 8 to 24 hours, and 6 to 12 hours.
• the molar ratio of the PDE9 inhibitor of the present disclosure and the at least one other active agent is not particularly restricted.
• the molar ratio of them may be in the range of 1 :500 to 500: 1, or of 1 : 100 to 100: 1, or of 1 :50 to 50: 1, or of 1 :20 to 20: 1, or of 1 :5 to 5: 1, or 1 :1.
• Similar molar ratios apply when a PDE9 inhibitor of the present disclosure and two or more other active agents are combined in a composition.
• the PDE9 inhibitor of the present disclosure may comprise a predetermined molar weight percentage from about 1% to 10%, or about 10% to about 20%, or about 20% to about 30%, or about 30% to 40%, or about 40% to 50%, or about 50% to 60%, or about 60% to 70%, or about 70% to 80%, or about 80% to 90%, or about 90% to 99% of the composition.
• the other active agent may be a different PDE9 inhibitor of the present disclosure or HU.
• the other active agent may also be an antibiotic agent such as penicillin, a nonsteroidal anti-inflammatory drug (NSAIDS) such as diclofenac or naproxen, a pain relief medication such as opioid, or folic acid.
• NSAIDS nonsteroidal anti-inflammatory drug
• Yet another aspect of the present disclosure provides methods of using a PDE9 inhibitor of the present disclosure in combination with at least one other therapy, such as but not limited to blood transfusion, bone marrow transplant, or gene therapy.
• kits and devices for conveniently and/or effectively carrying out methods of the present disclosure.
• kits will comprise sufficient amounts and/or numbers of components to allow a user to perform multiple treatments of a subject(s) and/or to perform multiple experiments.
• kits for treating sickle cell disease comprising a PDE9 inhibitor compound of the present disclosure or a combination of PDE9 inhibitor compounds of the present disclosure, optionally in combination with any other active agents, such as HU, an antibiotic agent such as penicillin, a nonsteroidal anti
• NSAIDS inflammatory drug
• diclofenac or naproxen a pain relief medication such as opioid, or folic acid.
• opioid a pain relief medication
• folic acid a pain relief medication
• the kit may further comprise packaging and instructions and/or a delivery agent to form a formulation composition.
• the delivery agent may comprise a saline, a buffered solution, or any delivery agent disclosed herein.
• the amount of each component may be varied to enable consistent, reproducible higher concentration saline or simple buffer formulations.
• the components may also be varied in order to increase the stability of PDE9 inhibitor compounds in the buffer solution over a period of time and/or under a variety of conditions.
• the present disclosure provides for devices that may incorporate PDE9 inhibitor compounds of the present disclosure. These devices contain in a stable pharmaceutical formulation available to be immediately delivered to a subject in need thereof, such as a human patient with sickle cell disease.
• Non-limiting examples of the devices include a pump, a catheter, a needle, a transdermal patch, a pressurized olfactory delivery device, iontophoresis devices, multi-layered microfluidic devices.
• the devices may be employed to deliver PDE9 inhibitor compounds of the present disclosure according to single, multi- or split-dosing regiments.
• the devices may be employed to deliver PDE9 inhibitor compounds of the present disclosure across biological tissue, intradermal, subcutaneously, or intramuscularly. More examples of devices suitable for delivering PDE9 inhibitor compounds include but not limited to a medical device for intravesical drug delivery disclosed in International Publication WO 2014036555, a glass bottle made of type I glass disclosed in ETS Publication No.
• a drug-eluting device comprising a film made of a degradable polymer and an active agent as disclosed in ETS Publication No. 20140308336, an infusion device having an injection micro-pump, or a container containing a pharmaceutically stable preparation of an active agent as disclosed in US Patent No. 5716988, an implantable device comprising a reservoir and a channeled member in fluid communication with the reservoir as disclosed in International Publication WO
• a hollow-fiber-based biocompatible drug delivery device with one or more layers as disclosed in US Publication No. 20090220612, an implantable device for drug delivery including an elongated, flexible device having a housing defining a reservoir that contains a drug in solid or semi-solid form as disclosed in International Publication WO 2013170069, a bioresorbable implant device disclosed in US Patent No. 7326421, contents of each of which are incorporated herein by reference in their entirety.
• a reference to“A and/or B,” when used in conjunction with open-ended language such as“comprising” can refer, in one embodiment, to A without B (optionally including elements other than B); in another embodiment, to B without A (optionally including elements other than A); in yet another embodiment, to both A and B (optionally including other elements).
• “or” should be understood to have the same meaning as“and/or” as defined above.
• “or” or“and/or” shall be interpreted as being inclusive, i.e., the inclusion of at least one, but also including more than one, of a number or list of elements, and, optionally, additional unlisted items. Only terms clearly indicated to the contrary, such as“only one of’ or“exactly one of,” or, when used in the claims,“consisting of,” will refer to the inclusion of exactly one element of a number or list of elements.
• the phrase“at least one” in reference to a list of one or more elements should be understood to mean at least one element selected from any one or more of the elements in the list of elements, but not necessarily including at least one of each and every element specifically listed within the list of elements and not excluding any combinations of elements in the list of elements.
• This definition also allows that elements may optionally be present other than the elements specifically identified within the list of elements to which the phrase“at least one” refers, whether related or unrelated to those elements specifically identified.
• “at least one of A and B” can refer, in one
• a“subject” or a“patient” refers to any mammal (e.g., a human), such as a mammal that may be susceptible to a disease or disorder, for example, tumorigenesis or cancer.
• a subject refers to one that has been or will be the object of treatment, observation, or experiment.
• a subject can be a subject diagnosed with cancer or otherwise known to have cancer or one selected for treatment, observation, or experiment on the basis of a known cancer in the subject.
• “treatment” or“treating” refers to amelioration of a disease or disorder, or at least one sign or symptom thereof.“Treatment” or“treating” can refer to reducing the progression of a disease or disorder, as determined by, e.g., stabilization of at least one sign or symptom or a reduction in the rate of progression as determined by a reduction in the rate of progression of at least one sign or symptom. In another embodiment,“treatment” or “treating” refers to delaying the onset of a disease or disorder.
• prevention or“preventing” refers to a reduction of the risk of acquiring or having a sign or symptom a given disease or disorder, i.e., prophylactic treatment.
• a therapeutically effective amount means that amount of a compound, material, or composition comprising a compound of the present teachings that is effective for producing a desired therapeutic effect. Accordingly, a therapeutically effective amount treats or prevents a disease or a disorder, e.g., ameliorates at least one sign or symptom of the disorder. In various embodiments, the disease or disorder is a cancer.
• a dash that is not between two letters or symbols is used to indicate a point of attachment for a substituent.
• -CONH 2 is attached through the carbon atom (C).
• (Ci- C 6 ) alkyls also include any one of Ci, C 2 , C 3 , C 4 , C 5 , C 6 , (Ci-C 2 ), (C1-C3), (Ci-C 4 ), (Ci-C 5 ), (C 2 - C 3 ), (C 2 -C 4 ), (C 2 -C 5 ), (C 2 -C 6 ), (C3-C4), (C3-C5), (C 3 -C 6 ), (C4-C5), (C 4 -C 6 ), and (C 5 -C 6 ) alkyls.
• ADME Absorption, Distribution, Metabolism, and Excretion
• AETC O -24 area under the concentration -time curve from time 0 to 24 hours postdose
• BBB blood-brain barrier
• cGMP cyclic guanosine monophosphate
• F cells blood cells with fetal haemoglobin
• HBB hemoglobin subunit beta
• HbF fetal hemoglobin
• HBG gamma-globin gene
• HbS sickle hemoglobin
• hERG human ether-a-go-go related gene
• IC 50 a half minimal inhibitory concentration
• ICAM-l intercellular adhesion molecule- 1
• ICP-MS inductively coupled plasma mass spectroscopy
• IV intravenous
• MTD maximum tolerated dose NO: nitric oxide
• NOAEL no-observed-adverse-effect level
• RBC red blood cell
• VOC vaso-occlusive crisis
• WBC white blood cell
• Compound 1 is an enantiomer of 6-[4-methyl-l-(pyrimidin-2- ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[l,5-a]pyrazin-8-one disclosed in WO 2013/053690.
• Compound 1 may be prepared from chiral-selective purification from 6-[4- methyl-l-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl-7H-imidazo[l,5- a]pyrazin-8-one prepared according to the method disclosed in WO 2013/053690, the contents of which are incorporated herein by reference in their entirety.
• Compound 1 may also be prepared with the method disclosed in WO 2017/005786, the contents of which are
• Compound 1 drug product to be used in ongoing clinical development is an immediate release tablet.
• the coating is may be used to assure uniformity of appearance across different tablet strengths and with the placebo.
• Each tablet comprises 20 mg, 50 mg, 100 mg, or 200 mg of Compound 1 drug substance (the monohydrate of the API) or placebo.
• Compound 1 drug substance the monohydrate of the API
• placebo A representative tablet composition is shown below in Table 1.
• All tablets were configured such that the target weight of the core tablets was 400 mg, and the target weight of the coated tablet was 440 mg. To accomplish this, the amounts of Compound 1 and Microcyrstalline Cellulose were adjusted accordingly. All other excipient amounts remained constant.
• Compound 1 drug substance was first processed by roller compaction to achieve a more uniform intermediate that is suitable for further blending and processing.
• a defined amount of API was passed through a roller compactor at 200-300 PSI and a roller speed of 4.0 RPM.
• the roller compacted material was passed through a 20-mesh screen to obtain a uniform particle size.
• the compacted and screened API was stored in double lined polyethylene bags pending use in tablet manufacturing.
• a defined amount of the roller compacted API was mixed with the defined excipients (excluding the coating solution) using a 16 qt. V-shell Blender. Blending was performed in a manner such that not less than 300 revolutions of the blender were completed in the defined period. Samples were taken from multiple locations in the V-Shell Blender to verify the blend uniformity.
• Blended material was stored in a suitable HDPE container within double lined polyethylene bags pending further processing.
• Tablet manufacturing was performed in a gravity fed tablet press with 11 mm upper and lower plain-faced tablet punches.
• the tablet press was adjusted to meet pre determined specifications for tablet weight, hardness, thickness, friability, and disintegration, as defined below. All core tablets are screened through a metal detector and de-dusted prior to film coating.
• a uniform coating mixture was prepared by mixing the defined amount of Opadry II White in Purified Water and mixing the suspension for no less than 45 minutes. Tablets were loaded on to the pan coating equipment and preheated to 43 °C prior to initiation of the coating operations. The preheated tablets were then coated in a 15-inch coating pan rotating at 10-15 RPM. The spray rate of the coating suspension was controlled at 10 grams per minute, and inlet air temperature maintained between 40-60°C.
• Tablets were sampled at defined intervals and weighed to determine if the desired target weight gain (10%) has been met. Once coating is completed the coated tablets were allowed to cool to ⁇ 30°C.
• Coated tablets were sampled for release testing and then transferred into a HDPE container double lined with double lined polyethylene bags.
• HPC-SSL-SFP Hydroxypropyl Cellulose
• Avicel PH200 Microcrystalline Cellulose
• HPC- SSL-SFP Hydroxypropyl Cellulose
• a hardness profile (tablet hardness vs. disintegration time) was established and samples were collected. Each sample was used to execute tablet physical testing to include weight, hardness, thickness, disintegration, and friability.
• Friability (USP Friability): no more than 0.3%, no capping.
• Disintegration per USP: All tablets completely disintegrate in no more than 15 minutes.
• Tablets from development batch was coated at target conditions to evaluate the core tablet ability to withstand pan coating. Prior to charging the tablets into the coating pan, the pan was sprayed with the Opadry II, 85F 18422, White and was allowed to dry. Operators monitored the spraying and drying process to ensure no flaking of the coating occurred. This created a thin layer of coating to prevent tablet defects caused by the coating pan such as scuffing. The tablets were coated to a 4.8% weight gain with Opadry II, 85F 18422, White. Results and Discussion:
• the goal of the development activities was to develop a formulation for the Compound 1 tablet which contained an optimal percent level of Hydroxypropyl Cellulose (HPC-SSL-SFP), yielding acceptable results.
• the formulation utilized was to produce a tablet with acceptable hardness, thickness, friability, and disintegration results.
• the tablets of each formulation were tested for hardness, thickness, friability, and disintegration.
• Target Results (1) Thickness: 4.50-4.80 mm, (2) Friability: ⁇ 0.3% loss, (3) Disintegration: ⁇ 15 minutes, and (4) Hardness of about lOkPa. Friability, disintegration and hardness were tested to USP Compounding standards (United States Pharmacopeia and National Formulary are recognized standards in testing).
• the first formulation evaluated contained 0.5% Hydroxypropyl Cellulose (HPC- SSL- SFP), this formulation is shown below in Table 4.
• the tablets were to be prepared with a target fill weight of 420.0 mg, a thickness range of 4.50mm -4.80mm.
• the goal was to have all tablets completely disintegrate in 15 minutes or less. According to the data in Table 5 all tablets completely disintegrated in less than 15 minutes, meeting the goal time. The remaining tablet blend was compressed, using the target fill weight of 420.0 mg.
• friability Another physical test performed was friability.
• the friability examines the tablets tendency for a tablet to chip, crumble or break following compression.
• the acceptance criteria for the batchs was a percent loss of 0.3% or less.
• the data collected during friability is shown below in Table 6.
• the disintegration times all exceeded the acceptance criteria of 15 minutes indicating failing results for disintegration.
• the increased disintegration time is caused by the increased Hydroxypropyl Cellulose (HPC-SSL- SPF) level. It can be noted that the loss after friability is less than 0.3%.
• Example 3 Compound 1 Reduces White Cell Adhesion and Activation
• PMN Polymorphic mononuclear cells
• SCD sickle cell disease
• activated neutrophils have been shown to be more adhesive to each other, platelets and the vascular endothelium.
• SCD sickle cell disease
• Compound 1 is able to increase expression of fetal hemoglobin in patient derived cells and murine models of SCD and reduce vessel occlusion in SCD murine models.
• sE-Selectin sE-Selectin
• E-Sel Endothelial E-selectin slows leukocyte rolling, which is followed by stationary adhesion and transmigration of activated leukocytes.
• Plasma levels of sE-Sel, produced by the enzymatic cleavage of the extracellular domains of E-Sel, are increased in SCD patients and this may be mediated by its interaction with leukocytes.
• plasma sE-Sel is increased 144% (139 mg/ml) over levels seen in control mice (57 mg/ml). This was reduced significantly in Townes mice treated with Compound 1, where plasma sE-Sel levels were elevated by only 61% over control mice (92 mg/ml).
• SC A sickle cell anemia
• HbSS homozygous sickle haemoglobin
• HU hydroxyurea
• Population A Following a Screening period of up to 4 weeks, eligible patients in Population A (i.e., those not receiving HU) receive either Compound 1 or placebo for a total of 24 weeks.
• patients are randomized 1 : 1 : 1 to receive oral Compound 1 30 mg, 50 mg, Compound 1 100 mg, or placebo daily for the first 12 weeks; for the second 12 weeks (Weeks 13-24), each patient’s dose may be doubled (i.e., from 50 mg to 100 mg; from 100 mg to 200 mg; or placebo).
• dose escalation does not affect study medication blinding.
• all available clinical data are reviewed approximately every 2 weeks, and dose escalation occurs on an individual patient basis on Day 85 only if approved based upon review of each patient’s individual clinical safety data.
• Population B Following a Screening period of up to 4 weeks, eligible patients in Population B (i.e., those receiving stable HU) enter a lead-in period and have blood samples drawn to characterize the PK profile of the patient’s prescribed dose of HU in the absence of Compound 1 (i.e., to characterize the patient’s baseline HU PK profile). Two full baseline HU PK profiles (with blood samples drawn over a 10-hour period at least 48 hours apart) are determined.
• Compound 1 dosing in Population B do not begin until at least 4 weeks of safety data from 6 patients in Population A have been reviewed and determined that it is safe and appropriate to begin dosing in Population B. Following approval to initiate dosing in
• Results from Population B are intended to provide information on Compound 1 when administered concomitantly with HU, both of which increase HbF levels through alternative biochemical pathways that increase intracellular cGMP. Because there are no clinical data to support administration of Compound 1 concomitantly with HU, patients in Population B initiate Compound 1 dosing at the low dose (30 mg or 50 mg) used in Population A and only escalate to the 100 mg dose if the 50 mg dose has been safe and tolerated for 4 weeks.
• Each patient must meet all of the following criteria to be enrolled in the study: 1. Male or female >18 or ⁇ 50 years of age. 2. Confirmed diagnosis of SCA (HbSS or sickle- bq thalassemia). Note, if not already documented in the patient’s record, the diagnosis of SCA must be confirmed via electrophoresis, HPLC, and/or genotyping. 3. Use of HU: For patients in the Population A: Have not received HU within 90 days prior to Screening and are not planning to take HU within the next 6 months. For patients in Population B: Have received HU for at least 6 months, have been on a stable dose for at least 60 days prior to Screening, and are not planning to change the dose level, dose regimen, or discontinue HU within the next 6 months.
• Female patients must not be pregnant and be highly unlikely to become pregnant. Male patients must be unlikely to impregnate a partner.
• HCV human immunodeficiency virus
• HCV hepatitis C
• HCV hepatitis B surface antigen
• HBsAg hepatitis B surface antigen
• ALT Alanine aminotransferase
• AST aspartate aminotransferase >3x the upper limit of normal (ULN).
• BMI Body Mass Index
• PDE5 inhibitors including but not limited to sildenafil, tadalafil, vardenafil
• a history of drug or alcohol abuse as judged by the investigator within the past lyear, or a positive alcohol
• cytochrome P450 enzymes including but not limited to cimetidine, cyclosporine, erythro ycin, omeprazole, rifampin, ritonavir, and St. John’s wort. If there is any question as to whether a substance is permitted, please review the product labelling (if applicable) and consult the Sponsor. 20. Consumption of grapefruit, grapefruit juice, or grapefruit products within 24 hours prior to Day 1 or planning to consume grapefruit products during the study. 21.
• any CYP3A sensitive substrates (excluding opioids), including but not limited to alfentanil, avanafil, budesonide, buspirone, conivaptan, darifenacin, darunavir, dasatinib, dronedarone, ebastine, eletriptan, eplerenone, everolimus, felodipine, ibrutinib, indinavir, lomitapide, lurasidone, maraviroc, midazolam, naloxegol, nisoldipine, quetiapine, saquinavir, sirolimus, tacrolimus, ticagrelor, tipranavir, tolvaptan, triazolam.
• opioids including but not limited to alfentanil, avanafil, budesonide, buspirone, conivaptan, darifenacin, darunavir, dasatinib, dronedarone, ebastine, eletrip
• P-gp P-glycoprotein
• any drugs or substances known to be significant substrates or inhibitors of P-glycoprotein including but not limited to cyclosporine, lovastatin, propranolol, quinidine, and simvastatin. If there is any question as to whether a substance is permitted, please review the product labelling (if applicable) and consult the Sponsor. 23. Other prior or ongoing medical condition, physical findings, or laboratory abnormality that, in the
• Compound 1 is supplied as 50, 100 or 200 mg white tablets and is administered orally with food. The different doses of Compound 1 are visually identical in tablet form.
• Placebo consists of tablets containing matrix absent Compound 1 and is identical in appearance to the Compound 1 tablets. Placebo is administered orally with food.
• the total duration of the study is approximately 32 weeks for Population A, including a Screening period of up to 4 weeks, a treatment period of 24 weeks, and a 4-week follow-up assessment after the last dose of study drug is administered.
• the total duration of the study is approximately 32 weeks for Population B, including a Screening period of up to 4 weeks, a lead-in period of approximately 8 weeks, a treatment period of 16 weeks, and a 4-week follow-up assessment after the last dose of study drug is administered.
• Hb Total haemoglobin
• HbF value %
• % F cells Indices of red cell haemolysis (unconjugated bilirubin, reticulocyte count, lactase dehydrogenase [LDH], and haptoglobin levels); Soluble E-selectin (sE-Sel), Soluble P- selectin (sP-Sel) and soluble intercellular adhesion molecule 1 (sICAM-l); High sensitivity-C reactive protein (hs-CRP).
• Compound 1 clinical outcomes as measured by pain-related measures (frequency, severity, and duration of pain; impact of pain/fatigue on work/school and on activities of daily living; need for/use of pain medication; SCA-related events requiring professional medical or health care, including events requiring hospitalization or therapies, such as transfusions) and in the physical, social, and emotional impact of SCA as measured by the Adult Sickle Cell Quality-of-Life Measurement Information System (ASCQ-Me).
• pain-related measures frequency, severity, and duration of pain; impact of pain/fatigue on work/school and on activities of daily living; need for/use of pain medication; SCA-related events requiring professional medical or health care, including events requiring hospitalization or therapies, such as transfusions
• ASCQ-Me Adult Sickle Cell Quality-of-Life Measurement Information System
• a separate blood sample is collected for confirmation of diagnosis by electrophoresis, high performance liquid chromatography (HPLC) and/or DNA sequencing (as needed) as well as for possible pharmacogenomic analyses of genes that may affect treatment response (including but not limited to alpha globin and BCL11 A).
• HPLC high performance liquid chromatography
• DNA sequencing as needed as well as for possible pharmacogenomic analyses of genes that may affect treatment response (including but not limited to alpha globin and BCL11 A).

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Hematology (AREA)
• Inorganic Chemistry (AREA)
• Diabetes (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Molecular Biology (AREA)
• Biophysics (AREA)
• Nutrition Science (AREA)
• Physiology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Priority Applications (14)

Applications Claiming Priority (2)

Related Child Applications (1)

Publications (1)

Family

ID=69643759

Family Applications (1)

Country Status (10)

Cited By (7)

Citations (5)

Family Cites Families (130)

• 2019
  • 2019-08-29 CA CA3110680A patent/CA3110680A1/en active Pending
  • 2019-08-29 MA MA053501A patent/MA53501A/fr unknown
  • 2019-08-29 WO PCT/US2019/048898 patent/WO2020047311A1/en not_active Ceased
  • 2019-08-29 KR KR1020217009591A patent/KR102831968B1/ko active Active
  • 2019-08-29 EP EP19853434.9A patent/EP3843737A4/en active Pending
  • 2019-08-29 CN CN202411939716.8A patent/CN119679736A/zh active Pending
  • 2019-08-29 JP JP2021510225A patent/JP7579239B2/ja active Active
  • 2019-08-29 CN CN201980071992.8A patent/CN112996512B/zh active Active
  • 2019-08-29 KR KR1020257022278A patent/KR20250108770A/ko active Pending
  • 2019-08-29 AU AU2019328299A patent/AU2019328299B2/en active Active
• 2021
  • 2021-02-23 IL IL281032A patent/IL281032A/en unknown
  • 2021-02-26 US US17/186,442 patent/US12213975B2/en active Active
• 2024
  • 2024-10-25 JP JP2024188068A patent/JP2025020208A/ja active Pending
  • 2024-12-20 US US18/989,150 patent/US20250120974A1/en active Pending
• 2025
  • 2025-05-19 AU AU2025203611A patent/AU2025203611A1/en active Pending

Patent Citations (5)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events